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Abstract 
Background: Impaired Toll-like receptor 2 (TLR2) function has been associated with the pathogenesis of atopic der-
matitis (AD). However, there are only few studies reporting on the TLR2-induced immunological responses of circulat-
ing leucocytes of AD patients. We thus investigated the expression and secretion of Th1, Th2 and Th17/22 cytokines 
triggered by TLR2 ligands in human peripheral blood mononuclear cells (PBMCs) from AD patients. Expression of 
TLR2, 1, 6 and high-affinity receptor for IgE (FcεRI) were further investigated to evaluate the outcome of immune 
response in AD.
Methods: Expression of TLR2, 1, 6 and FcεRI in PBMCs from AD patients and healthy individuals were measured by 
qPCR. Subsequent to stimulation with TLR2 ligands PGN and Pam3CSK4, expression and secretion of Th1, Th2 and 
Th17/22 cytokines were investigated by qPCR and ELISA.
Results: The levels of TLR2, 1, 6 mRNA were not altered in both groups of subjects while that of FcεRI was increased 
in AD patients. Subsequent to the activation by TLR2 ligands, PBMCs from AD patients significantly released less IFN-γ, 
IL-17F and IL-22 than those from healthy controls while no detectable level of release was observed with the other 
cytokines. In contrast, significantly higher levels of mRNA expression for TNF-α, IL5, IL-17A and IL-22 were observed in 
TLR2 activated PBMCs of AD patients than those of healthy control.
Conclusions: PBMCs from AD patients are defective in the secretion of Th1 and Th17/22 cytokines in response to 
TLR2 ligands. The inconsistent increased expression of the mRNA for the corresponding Th1 cytokines and the Th2 
cytokines IL-5 suggested that there may be alterations of downstream signaling events in the cytokine release mecha-
nisms of PBMCs that are associated with the development of AD.
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Background
Atopic dermatitis (AD) is the most common chronic 
inflammatory skin disease which affects 10–20  % 
children and 1–3 % adults worldwide [1]. The pathogene-
sis of AD is multifactorial with complex genetic and envi-
ronmental influences. However, patients with AD have 
frequent bacterial skin infection indicating that immune 
abnormalities, especially innate immune dysfunctions, 
are critical for the pathogenesis of AD. Over 90 % of AD 
patients are colonized with Staphylococcus aureus (S. 
aureus) on lesional and non-lesional skin [2]. S. aureus 
could induce persistent inflammation in AD patients 
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the amelioration of disease severity [2, 3]. The Toll-like 
receptors (TLRs) family which belongs to the pattern-
recognition molecules/receptors (PRRs) is at the center 
of detection mechanisms for the innate immunity. TLR2 
recognizes S. aureus and is responsible for host defense 
against S. aureus infection [4]. In this regard, dysfunction 
in TLR2 signaling has been suggested to be involved in 
the development of AD.
Patients carrying a R753Q mutation in TLR2 or with 
TLR2–16934A  >  T polymorphism frequently develop 
severe AD [5, 6]. Furthermore, TLR2-mediated release 
of inflammatory mediators from immune effector cells 
(T cells, B cells, mast cells, eosinophils, macrophages and 
dendritic cells) and structural cells (keratinocytes and 
epithelial cells) are defective in AD patients, and thus 
partially explained the increased susceptibility to patho-
gens infection. These inflammatory mediators include 
TNF, IL-1, IL-6 and IL-8 [7–9]. However, the modula-
tory effect of TLR2 activation on priming the immune 
response in AD remains unclear.
It has been shown that the immunological milieu of 
AD is dominated by Th2-skewed immune response [10]. 
Augmentation of Th2 response could be the result of 
enhanced Th2 signaling or deficient Th1 response. How-
ever, there is no systematic analysis on the Th1- and Th2-
derived cytokines in TLR2-mediated immune response in 
AD patients. Meanwhile, Th17/22 cytokines are recently 
indicated to regulate the pathogenesis of AD by regulating 
the expression of various cytokines and chemokines [3, 
11]. However, whether Th17/22 response to TLR2 stimuli 
is impaired in AD patients is not yet known. In this study, 
we employed PBMCs isolated from healthy controls or 
AD patients to examine the expression and secretion pro-
file of T helper cytokines in these cells upon TLR2 acti-
vation. Two classical TLR2 ligands peptidoglycan (PGN) 
and tripalmitoyl-S-glycero-Cys-(Lys)4 (Pam3CSK4) were 
applied in the investigation. While PGN is a primary cell 
wall component of Gram-positive bacteria which acti-
vates TLR2 and TLR6 heterodimer, Pam3CSK4 is a syn-
thetic tripalmitoylated lipopeptide which promotes the 
formation of TLR2 and TLR1 heterodimer [4]. In gen-
eral, we observed that PBMCs from AD patients showed 
reduced secretion of Th1 and Th17/22 cytokines, whereas 
the mRNA expression of the Th2 cytokine IL-5 and the 
AD-related receptor FcεRI were increased. Such change 
may cope with the pathogenesis of AD in humans in the 
context of distorted balance between immune cell medi-
ated inflammation and infection clearance.
Methods
Blood samples
Heparinized blood was obtained from 40 patients suf-
fering from AD according to the criteria of Hanifin and 
Rajka (27 female, 13 male, mean age 31  years, range 
20–45  years) with moderate to severe disease activity 
[12], while 43 healthy individuals (29 female, 14 male, 
mean age 29 years, range 20–42 years) served as controls. 
Study procedures were reviewed and approved by eth-
ics committee of Peking University Shenzhen Hospital 
Board.
Culture and stimulation of PBMCs
PBMCs were separated from peripheral blood by Ficoll–
Hypaque density gradient centrifugation. Cells were 
suspended at 1 × 106/mL in complete culture medium 
(RPMI 1640 supplemented with 2  mmol/L l-glutamine, 
penicillin–streptomycin, 10  % fetal bovine serum (all 
from Invitrogen, Carlsbad, USA) and 55  μM 2-Mercap-
toethanol (GIBCO, Eggestein, Germany). PBMCs were 
stimulated with 1  μg/mL PGN from S. aureus (Sigma-
Aldrich, Deisenhofen, Germany) or Pam3CSK4 (Invivo-
gen, San Diego, California, USA) for 8 h or 48 h for the 
RT-PCR and immunoassay studies respectively. These 
time points were determined by preliminary time course 
studies which demonstrated optimal mRNA expression 
and protein secretion of cytokines respectively.
RNA extraction and qRT‑PCR
At the end of the 8 h incubation with TLR2 ligands, cell 
pellets were collected by centrifugation and were then 
lysed with TRIzol reagent for the extraction of RNA. 
Total RNA was isolated with TRIzol reagent and was 
quantified by measuring the ratio of A260nm/A280nm. RNA 
(1 μg) was then reverse transcribed with the Revert Aid 
First Strand cDNA Synthesis Kit (Thermo scientific, 
Waltham, MA, USA). The RT mixture was incubated 
for 50 min at 42  °C followed by 15 min at 70  °C. qPCR 
was performed using the SYBR Green Dye method 
which was carried out using cDNAs supplemented with 
SYBR Green supermix (Bio-rad, Hercules, CA, USA) 
and 100  nM paired primers for different genes to be 
analyzed in PCR buffer. The PCR protocol consisted of 
a cycle at 95 °C for 5 min followed by 40 cycles consist-
ing of 15 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. The 
2−△△Ct method was used for quantification of the target 
gene expression. All tests were done in triplicates. The 
average Ct was calculated for the target genes and inter-
nal control (GAPDH) and the ΔCt (Ct,target − Ct,GAPDH) 
values were determined. Fold expression change of target 
genes in AD patients was determined relative to controls 
as 2−ΔΔCt, where ΔΔCt = ΔCt (patient or control) − ΔCt 
(average for controls).
Immunoassays
Cell culture medium was collected after 48 h incubation. 
Secretion of TNF-α, IFN-γ, IL-4, IL-5, IL-12, IL-17A, 
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IL-17F, IL-18, IL-22, IL-31, IL-33 and TSLP from PBMCs 
was determined by commercial enzyme-linked immuno-
sorbent assay (ELISA) kits (eBioscience, San Diego, CA, 
USA and PeproTech, New Jersey, USA). Spontaneous 
release of the above cytokines was undetectable in both 
healthy controls and AD patients.
Statistical analysis
Statistical significance was determined by using an 
unpaired student t test to compare samples from patients 
with those of healthy individuals. Differences were con-
sidered significant at a P value of less than 0.05.
Results
Altered Th1 cytokines production in PBMCs from AD 
patients upon stimulation with TLR2 ligands
To investigate the role of TLR2 activation in AD devel-
opment and inflammation, we examined the expression 
and secretion of inflammatory cytokines by PBMCs upon 
TLR2 activation. After incubation with TLR2 ligands 
for 8 h, the level of TNF-α mRNA expression in PBMCs 
from AD patients was significantly higher than that from 
healthy individuals (Fig.  1a). In contrast, TLR2 ligands 
stimulation did not alter the mRNA expression of IFN-
γ, IL-12 and IL-18 in PBMCs of AD patients when com-
pared with those of healthy controls (Fig. 1b–d).
Incubation of PBMC with TLR2 ligands for 48 h trig-
gered the release of IFN-γ and TNF-α, but not IL-12 and 
IL-18. The levels of release of these two cytokines induced 
by PGN were higher than those induced by Pam3CSK4. 
Furthermore, the release of IFN-γ from PBMCs stimu-
lated with both TLR2 ligands was almost abolished in AD 
patients, whereas no significant difference was observed 
in the release of TNF-α between AD patients and healthy 
individuals (Fig. 2).
Augmented production of Th2 cytokine in PBMCs from AD 
patients upon stimulation with TLR2 ligands
Among the Th2 cytokines studied, the mRNA level 
of IL-13, IL-31 and TSLP were comparable between 
the PMBCs of both AD patients and healthy control 
(Fig. 3b, c, e). In contrast, the level of IL-33 mRNA was 
less upregulated by TLR2 signaling in AD patients than 
that in healthy controls (Fig.  3d) while TLR2/1 ligand 
Pam3CSK4 induced dramatically higher level of IL-5 
mRNA in AD patients (Fig.  3a). The basal level of IL-4 
mRNA in PBMCs was undetectable in AD patients and 
healthy individuals (using four different primers specifi-
cally targeted for IL-4), nor did TLR2 activation triggered 
the expression of IL-4 (data not shown).
Neither of the TLR2 ligand triggered the release of IL-4, 
IL-5, IL-31, IL-33 or TSLP from PBMCs in AD patients 
and healthy controls (data not shown).
Altered Th17/22 cytokines production in PBMCs from AD 
patients upon stimulation with TLR2 ligands
PGN induced significantly higher mRNA expression of 
IL-17A and IL-22 in PBMCs of AD patients (Fig.  4a, c) 
while, both TLR2-ligands reduced the expression of IL-
17F mRNA in PBMCs isolated from AD patients than 
that from healthy controls (Fig. 4b).
Secretion of IL-17F and IL-22 from AD patient derived 
PBMCs upon TLR2 activation was significantly lower. 
There was no release of IL-17A from PBMCs stimulated 
with TLR2 ligands in both groups (Fig. 5).
No change of TLR2, TLR1 and TLR6 expression from PBMCs 
in AD patients
Reduced TLR2 expression was observed in many other 
cells types including macrophage, T cells, skin epithelium 
in AD patients [8, 9, 13]. However, the mRNA expres-
sion level of TLR2, TLR1 and TLR6 from PBMCs was not 
altered in AD patients compared with healthy controls 
(Fig. 6a).
Enhanced expression of FcεRI from PBMCs 
upon stimulation with TLR2 ligands
The high-affinity receptor for IgE (FcεRI) is key com-
ponent in the induction of AD [14]. In AD patients, 
basal mRNA levels of the three FcεRI receptor subu-
nits (FcεRIA, FcεRIG and Ms4A) were not altered in 
AD patients and healthy individuals (Fig.  6b). When 
stimulated with TLR2 ligands, mRNA levels of FcεRIA 
and FcεRIG in PBMCs were significantly higher in AD 
patients than those in healthy controls (Fig. 7a, b).
Discussion
Increased susceptibility to skin S. aureus infection and 
defect in TLR2 signaling have been regarded as specific 
features reflecting the immune dysfunction in AD. A 
growing body of evidence suggests that innate immu-
nity not only provides a rapid antimicrobial host defense, 
but also determines the type of subsequent acquired 
immune responses through directing the groups of 
cytokines released by activated immune cells [15]. In the 
current study, we observed a reduced Th1 and Th17/22 
cytokines secretion, an enhanced mRNA expression of 
Th2 cytokine IL-5 and FcεRI from PBMCs upon TLR2 
stimuli in AD patients. The different cellular responses 
demonstrated between AD patients and healthy con-
trols suggested that initiation of innate immune reactions 
through TLR2 activation could eventually lead to a Th2-
dominant inflammation in AD patients.
TLR2 is important in driving Th1 response to 
cutaneous sensitization through promoting the 
IFN-γ  response  to cutaneously introduced antigens 
[16]. However, we showed that TLR2-mediated IFN-γ 
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Fig. 1 Effects of Toll-like receptor 2 (TLR2) ligands on mRNA expression of Th1 cytokines from human peripheral blood mononuclear cells (PBMCs) 
in atopic dermatitis (AD) patients. PBMCs were incubated with PGN or Pam3CSK4 for 8 h. TNF-α (a), IFN-γ (b), IL-12 (c) and IL-18 (d) mRNA expression 
from PBMCs was determined by qPCR. Data were shown as 2−ΔΔCt ± SEM. T-test was employed to compare the significant difference between AD 
patients and healthy individuals. ***p < 0.001
Fig. 2 Effects of TLR2 ligands on the release of Th1 cytokines from PBMCs in AD patients. PBMCs were incubated with PGN or Pam3CSK4 for 48. 
Release of TNF-α (a) and IFN-γ (b) from PBMCs was determined by ELISA. Data are shown as mean ± SEM. T-test was employed to compare the 
significant difference between AD patients and healthy individuals. **p < 0.01, ***p < 0.001
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secretion from PBMCs was almost abolished in AD 
patients. Consistent with our results, IFN-γ deficiency 
was generally observed in PBMCs at basal level or upon 
stimulation by other ligands including lipopolysaccha-
ride (LPS), Staphylococcal enterotoxin B (SEB), house 
dust mite (HDM), Candida albicans (CA) and phytohae-
magglutinin (PHA) in AD patients [17–19]. These obser-
vations confirm a general intrinsic cellular deficiency 
in IFN-γ response in PBMCs from patients with AD. 
IL-12 and IL-18 are inducers for IFN-γ expression [20], 
however, the mRNA expression IL-12 and IL-18 did not 
display noticeable difference from PBMCs triggered by 
TLR2 ligands in AD patients compared with healthy con-
trols, nor did TLR2-ligands stimulated the release of the 
two cytokines in both groups. In contrast, a significantly 
reduced TLR2-mediated expression of IL-33 mRNA in 
PBMCs was observed in AD patients. IL-33 is a newly 
characterized cytokine belonging to the IL-1 cytokine 
family that drives Th2 response [21]. However, Seltmann’s 
group recently pointed out an important regulatory loop 
of IFN-γ and IL-33 in eczematous skin inflammation [22]. 
IFN-γ induced epithelial IL-33 expression which in turn 
acted on activated T cells to further improve the release 
of IFN-γ, indicating that IL-33 may act as a dual func-
tion cytokine which directs either Th1- or Th2-linked 
inflammation [22]. The impairment in TLR2-mediated 
IL-33 and IFN-γ production provides a potential mecha-
nism for the deficiency in IFN-γ response in AD patients 
upon TLR2 activation.
Similar to the defect in IFN-γ production, impaired 
TLR2-mediated release of TNF-α from PBMCs was also 
observed in AD patients by other groups [7]. However, 
we showed that the level of TNF-α secretion from TLR2 
ligands-stimulated PBMCs was slightly lower in AD 
patients, while the mRNA level of TNF-α elevated dra-
matically, implying that TLR2 signaling could be ampli-
fied in AD patients at the transcriptional level. Moreover, 
although the mRNA expression of IFN-γ from TLR2-
ligands stimulated PBMCs was similar between AD 
patients and health control, the release of IFN-γ from 
PBMCs upon TLR2 activation was almost abolished in 
AD patients. The inconsistency in the mRNA expression 
and secretion of TNF-α and IFN-γ suggests a post-tran-
scriptional or secretion defect in Th1 response in PBMCs 
from patients with AD.
Although TLR2 ligands did not induce the release of 
Th2 cytokines, it dramatically increased the IL-5 mRNA 
expression in AD patients. IL-5 is known to play a piv-
otal role as a major maturation and differentiation factor 
for eosinophils, which participate in AD pathogenesis 
Fig. 3 Effects of TLR2 ligands on mRNA expression of Th2 cytokines from PBMCs in AD patients. PBMCs were incubated with PGN or Pam3CSK4 
for 8 h. IL-5 (a), IL-13 (b), IL-31 (c), IL-33 (d) and TSLP (e) mRNA expression from PBMCs was determined by qPCR. Data were shown as 2−ΔΔCt ± SEM. 
T-test was employed to compare the significant difference between AD patients and healthy individuals. **p < 0.01
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Fig. 4 Effects of TLR2 ligands on mRNA expression of Th17/22 cytokines from PBMCs in AD patients. PBMCs were incubated with PGN or Pam3CSK4 
for 8 h. IL-17A (a), IL-17F (b) and IL-22 (c) mRNA expression from PBMCs was determined by qPCR. Data were shown as 2−ΔΔCt ± SEM. T-test was 
employed to compare the significant difference between AD patients and healthy individuals. *p < 0.05, **p < 0.01
Fig. 5 Effect of TLR2 ligands on the release of Th17/22 cytokines from PBMCs in AD patients. PBMCs were incubated with PGN or Pam3CSK4 for 
48 h. Release of IL-17F (a) and IL-22 (b) from PBMCs was determined by ELISA. Data are shown as mean ± SEM. T-test was employed to compare the 
significant difference between AD patients and healthy individuals. ***p < 0.001
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Fig. 6 Quantitative analysis of mRNA expression of TLR2, 1, 6 (a) and subunits of FcεRI (b) from PBMCs in AD patients. Their relative expression was 
calculated using the 2−ΔΔCt method. Data were shown as 2−ΔΔCt ± SEM. T-test was employed to compare the significant difference between AD 
patients and healthy individuals
Fig. 7 Effect of TLR2 ligands on mRNA expression of subunits of FcεRI from PBMCs in AD patients. PBMCs were incubated with PGN or Pam3CSK4 
for 8 h. FcεRIA (a), FcεRIG (b) and Ms4A (c) mRNA expression from PBMCs was determined by qPCR. Data were shown as 2−ΔΔCt ± SEM. T-test was 
employed to compare the significant difference between AD patients and healthy individuals. **p < 0.01
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[23]. Elevation in IL-5 mRNA expression would promote 
the Th2-skewed response in the context of the co-exist-
ence of other allergens such as house dust mite extracts, 
which could induce the release of IL-5 from PBMCs [19]. 
Although recent study has shown that TLR2 stimulation 
down-regulated FcεRI expression on epidermal Langer-
hans cells (LC) which play critical role in AD, we showed 
that TLR2-mediated FcεRI expression was elevated in 
PBMCs from AD patients. Allergen binding is mediated 
via IgE-bound FcεRI, which is highly expressed on epi-
dermal dendritic cells, eosinophils, basophils and mast 
cells in AD, and once activated, triggers the release of 
Th2 cytokines including IL-5 [14, 24]. Synergistic effect 
of TLR2 activation on FcεRI-mediated response has been 
demonstrated in the literature [25, 26]. Furthermore, 
synergistic effects on FcεRI- and TLR-triggering could 
promote Th2 differentiation of human naive CD4+ cells 
[27]. In this regard, the augmented TLR2-mediated IL-5 
and FcεRI mRNA expression in AD patients would fur-
ther aggravate Th2-biased response in AD development 
in the co-existence of allergens which activate the FcεRI 
signaling.
Th17 cells produce Th17 and Th22 cytokines which 
are involved in the development of some autoimmune 
diseases [28]. Although Th17 cells are known to contrib-
ute to the pathogenesis of psoriasis, their roles in AD 
remain controversial. Increased number of Th17 cells 
was observed in the peripheral blood and skin lesion of 
patients with acute AD, whereas reduced IL-17 produc-
tion was found in chronic AD patients [28, 29]. Further-
more, the decrease of circulating IFN-γ negative Th17 
cells correlated with increased of CCL17, IgE and eosino-
phil levels in AD patients, indicating that decrease in cir-
culating Th17 cells might contribute to the induction of 
AD [11]. The involvement of IL-17 immunity in the devel-
opment of atopic march induced by enterotoxin B (SEB) 
from S. aureus has been first addressed by Zheng’group 
[30]. Epicutaneous exposure of SEB exaggerated sys-
temic Th17/IL-17A immunity and enhanced allergic lung 
inflammation [30]. In the current study, TLR2-mediated 
release of IL-17F was abolished in AD patients while IL-
17A release was not detected in either AD patients or 
healthy controls. However, TLR2 ligands trigger signifi-
cantly larger amount of IL-17A mRNA expression in AD 
patients. Although IL-17A and IL-17F both belong to the 
IL-17 cytokine family and share the strongest sequence 
homology, recent studies have pointed out that IL-17A 
and IL-17F induce the release of different pro-inflamma-
tory cytokines. In a mouse model of asthma, IL-17F−/− 
mice exhibited enhanced Th2 response and eosinophil 
infiltration, while IL-17A−/− mice showed the opposite, 
suggesting a suppressive role for IL-17F and a promo-
tional role for IL-17A in the induction of asthma through 
regulating the Th2 response [31]. The impaired IL-17F 
response but enhanced IL-17A mRNA expression from 
PBMCs triggered by TLR2 ligands in AD patients may 
therefore contribute to a more complicated mechanism 
to the pathogenesis of AD through exacerbating the Th2 
response in AD development.
On the other hand, the number of IL-22+CD8+T-cell 
is correlated with chronic AD disease severity [32]. How-
ever, we showed that TLR2-mediated IL-22 secretion 
was also severely impaired in AD patients. In contrast 
to the secretion of IL-22, the mRNA expression level of 
IL-22 was significantly higher in AD patients than that in 
healthy group, implying a post-transcriptional or secre-
tion defect in PBMCs from AD patients. Such inconsist-
ency of TLR2-mediated cytokine secretion and mRNA 
expression was observed in all the other cytokines 
examined including TNF-α, IFN-γ, and IL-17F where 
impairment in the cytokines secretion but enhance-
ment or no change in mRNA expression were observed 
in AD patients compared with healthy controls. Consist-
ent with our finding, impaired secretion but not mRNA 
expression of IL-6 and IL-8 was detected in macrophages 
isolated from PBMCs upon TLR2 stimulation in AD 
patients [9]. Taken together, we suggest that impairment 
of TLR2-mediated Th1 and Th17/22 cytokines secretion 
was more likely due to the defects in PBMC themselves 
in addition to the impairment in TLR2 signaling. Indeed, 
the phenotypical and functional defect of immune effec-
tor cells in AD patients have also been addressed by other 
groups [15, 17]. Natural killer (NK) cells and γδ+T cell 
were prone to undergo apoptosis on cell-to-cell contact 
with activated monocytes from patients with AD [15]. 
Similarly, reductions in the number of IFN-γ-producing 
cells and the amount of IFN-γ production per cell were 
observed in children with AD [17]. In this study, further 
investigation of TLR2, 1 and 6 mRNA expressions did 
not show any significant difference between AD patients 
and healthy controls suggesting that the impaired TLR2-
mediated cytokines secretion in AD patients could not be 
explained by changes in TLR2 expression. On the other 
hand, studies have shown that defects in certain sec-
ond messengers such as the cyclic AMP, protein kinase 
C and inositol involved in signaling systems have been 
suggested to provide a biochemical mechanism for the 
impairment of cytokines secretion seen in AD [33, 34]. 
Further studies are necessary to reveal the defects or dys-
functions of PBMCs at both the cellular and molecular 
levels in AD.
Conclusions
In summary, TLR2-mediated responses were com-
promised in their capacity to secrete Th1 and Th17/22 
cytokines. However, TLR2 activation enhanced the 
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expression of Th2 cytokine IL-5 and FcεRI, thereby 
directing subsequent acquired immune responses toward 
a Th2-biased pattern, which in turn increases the risk 
for bacterial colonization and thus worsen clinical out-
comes of patients as previously reported [35]. Further-
more, we showed for the first time the inconsistency in 
TLR2-mediated secretion and mRNA expression of Th1 
and Th17/22 in PBMCs from AD patients, implying an 
intrinsic cellular defect or dysfunction of PBMCs them-
selves in the secretion of Th1 and Th17/22 cytokines in 
AD patients. Further investigation is required to eluci-
date the functional defect of PBMC from patients with 
AD to explain the imbalance in innate immunity as well 
as acquired immunity in AD development.
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